← Leaderboards
Chien-Fu Hung
Johns Hopkins University
$6,457,345
Attributed
$8,449,061
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,449,061 · 11
By mechanism
P50$3,169,777 · 4
R01$2,952,941 · 1
R21$2,326,343 · 6
Top collaborators
- Richard Bruce Roden5 shared
- Raphael Paul Viscidi5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard Bruce Roden$11,133,737
- Tamara Levin Lotan$5,309,336
- Donald Small$15,602,119
- Brandon Krishna Lam$127,744
- Maura L Gillison$5,649,784
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusAntigensImmunogenicityMalignant NeoplasmsHuman Papillomavirus 16TumorMalignant Neoplasm Of Cervix UteriHuman Papilloma Virus InfectionVaccinationExhibitsVaccinatedImmuneVaccinesProteinsCd4 Positive T LymphocytesHuman Papilloma Virus VaccineImmune ResponseHpv-High RiskCellular ImmunityNovel VaccinesIn VivoInfectionMediatingT Cell Response
Grant awards (29)
Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL$327,053
P50 · FY2025 · CA · contact PI
Salmonella derived nanoparticles for cancer immunotherapy$204,688
R21 · FY2025 · DE · contact PI
Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL$283,663
P50 · FY2024 · CA · contact PI
Mouse modeling of HPV infection$581,637
R01 · FY2023 · CA · contact PI
Mouse modeling of HPV infection$582,604
R01 · FY2022 · CA · contact PI
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancer$187,556
R21 · FY2022 · CA · contact PI
Mouse modeling of HPV infection$595,447
R01 · FY2021 · CA · contact PI
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of Salmonella$245,625
R21 · FY2021 · DE · contact PI
Novel strategy combined with targeted radiation therapy unleashes potent antitumor immunity in HPV + head and neck cancer$229,659
R21 · FY2021 · CA · contact PI
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccine$229,659
R21 · FY2021 · CA · contact PI
Mouse modeling of HPV infection$596,384
R01 · FY2020 · CA · contact PI
Electroporation delivery of pNGVL4aCRTE6E7L2 DNA for treatment of HPV16+ CIN2/3 patients$292,495
P50 · FY2020 · CA · contact PI
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of Salmonella$204,688
R21 · FY2020 · DE · contact PI
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccine$191,383
R21 · FY2020 · CA · contact PI
Mouse modeling of HPV infection$596,869
R01 · FY2019 · CA · contact PI
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation$252,218
P50 · FY2018 · CA · contact PI
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation$257,782
P50 · FY2017 · CA · contact PI
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation$241,270
P50 · FY2016 · CA · contact PI
Innovative Strategy to Generate Antigen-Specific Cytotoxic Lymphocytes$211,410
R21 · FY2016 · CA · contact PI
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation$243,724
P50 · FY2015 · CA · contact PI
Molecular pathogenesis and host response following persistent E6/E7 expression$243,000
R21 · FY2015 · AI · contact PI
Innovative Strategy to Generate Antigen-Specific Cytotoxic Lymphocytes$176,175
R21 · FY2015 · CA · contact PI
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation$241,080
P50 · FY2014 · CA · contact PI
Molecular pathogenesis and host response following persistent E6/E7 expression$202,500
R21 · FY2014 · AI · contact PI
Immunology Core$203,621
P50 · FY2013 · CA
Immunology Core$217,513
P50 · FY2012 · CA
Immunology Core$214,443
P50 · FY2011 · CA
Immunology Core$210,854
P50 · FY2010 · CA
Immunology Core$184,061
P50 · FY2009 · CA